This is an estimated date of earnings release. Earnings Date-Ex Div Date 09/29/2020; Div Amount 21.00; Split Date-Split Factor-Latest Astellas Pharma Inc News. Strategic Plan 2018; Financial Information. Diary of Japan (.N225) corporate earnings for the week ahead JAPAN EARNINGS Start Date Start RIC Company Name Event Name Time 11-May-2020 02:30 9107.T Kawasaki Kisen … A high-level overview of Astellas Pharma Inc. (ALPMF) stock. Analysts on Wall Street predict Astellas Pharma will release earnings per share of ¥29.99. Astellas Pharma (ALPMY) reported 3rd Quarter December 2020 earnings of $0.31 per share on revenue of $3.1 billion.. Astellas Pharma Inc and its subsidiaries are engaged in manufacturing, marketing and import/export of pharmaceuticals. Company Participants. Financial Highlights; Financial Data (Annual Data) Financial Data (Quarterly Data) Sales of Major Products ; Revenue by Region; Annual Report; IR Library. Last Earnings Release: N/A; Next Ex-Dividend Date: N/A; Last Ex-Dividend Date: Sep. 29, 2020; Description: Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. News . The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. Astellas Pharma PE ratio as of February 02, 2021 is 18.94. Earnings Date-Ex Div Date 09/29/2020; Div Amount 21.00; Split Date-Split Factor-Latest Astellas Pharma Inc News. Get today's Astellas Pharma Inc. stock price and latest 4503 news as well as Astellas Pharma Inc. real-time stock quotes, technical analysis, full financials and more. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. There is no recent news for this security. Latest Developments More. Earnings date: N/A: Forward dividend & yield: 0.36 (2.60%) Ex-dividend date: 30 Mar 2021: 1y target est: N/A: All. ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer You will enter external sites beyond here. Company: Astellas Pharma Co. Ltd. Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. Astellas Pharma Completes Acquisition Of Iota Biosciences. Astellas Pharma (ALPMY) Recent Earnings. Astellas Pharma Inc (OTCPK:ALPMF) Q3 2021 Earnings Conference Call January 29, 2021 2:00 AM ET. Wall Street analysts expect Astellas Pharma will release earnings per share of ¥30.25. On May 14, Astellas Pharma is presenting Q4 earnings. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. PR Newswire. Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy. The latest earnings, revenues and financial reports for Astellas Pharma Inc. (4503). There is no recent news for this security. Astellas Pharma Inc. … Replays of most recent earnings release conference calls; Calendar of events (including upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors) Corporate Governance information; About Astellas . Astellas Pharma Inc (OTCPK:ALPMF) Q1 2021 Earnings Conference Call August 4, 2020 3:00 AM ET. Astellas Pharma will report earnings from the last quarter on January 29. Vesomni 6 mg/0.4 mg modified release tablets. Track Astellas Pharma stock price in real-time ahead here. Active Ingredients: Solifenacin succinate, Tamsulosin Hydrochloride . View the latest Astellas Pharma Inc. (ALPMF) stock price, news, historical charts, analyst ratings and financial information from WSJ. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. (1) Consolidated financial results of Yamanouchi Pharmaceutical Co., … Earnings: The amount and date of latest Earnings Per Share (EPS) paid out to shareholders. Astellas Pharma Inc. TEL +81-3-3244-3201 Release for the financial results of Astellas for FY2004 Japan, May 17, 2005 - Astellas Pharma Inc. today announced the financial results of former Yamanouchi Pharmaceutical Co., Ltd. and former Fujisawa Pharmaceutical Co., Ltd. for FY2004 (fiscal year ended March 31, 2005). Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). Analysts on Wall Street expect Astellas Pharma will release earnings per share of $0.308. Astellas Pharma Inc. (TSE: 4503) announced today that it had extended its all-cash tender offer for $57.50 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) to 12:00 midnight New York City time on Wednesday, June 2, 2010, unless further extended. Royalty income makes up a small percentage of Astellas' overall sales. On October 30, Astellas Pharma will release earnings for the most recent quarter. Q3 2021 Astellas Pharma Inc Earnings Release. Thank you for visiting the Astellas Pharma Inc. Website. Astellas shares fell in afternoon trading after the earnings release, closing down 2% at 1,544 yen amid investor concern about a looming patent cliff. Naoki Okamura – Representative Director and Executive Vice President. Sponsor: Astellas Pharma Australia Pty Ltd January 2014 . Wall Street predict expect Astellas Pharma will release earnings per share of ¥22.35. The Astellas Pharma Inc PE ratio based on its reported earnings over the past 12 months is 24.68.The shares are currently trading at ¥1849.5.. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Get News Alerts by Email Year All Years 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 Category All Categories Corporate Corporate Awards Corporate Social Responsibility Our People Therapeutic Area News Uncategorized Keywords Go On August 4, Astellas Pharma will present their latest quarterly figures. Royalty income makes up a small percentage of Astellas' overall sales. TOKYO, March 11, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer … It is based on a 36-month historical regression of the return on the stock onto the return on the S&P 500. EPS: The annual earnings per share. (This link opens in a new window) Cancel Click here to leave this site. Company Participants. OSI is now a wholly-owned subsidiary of Astellas US Holding, Inc., a holding company owned by Astellas Pharma Inc., and OSI's common stock has ceased to … Get the latest Astellas Pharma Inc. ALPMY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Earnings Momentum Score Average 47.79 Login to Access: 47.79 Login to Access: Dividend Quality Score Average 100 Login to Access: Login to Access: Fundamental Score Above Average 82 Login to Access: 29.00 Login to Access: Dividend Yield (%) Average 2.31 Login to Access: 1.16 Login to Access: Next release date Last Earnings Release: N/A; Next Ex-Dividend Date: N/A; Last Ex-Dividend Date: Sep. 28, 2020; Description: Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. Investors. There is no recent news for this security. Astellas Receives … Press releases. Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan. Earnings Date-Ex Div Date 09/25/2020; Div Amount 0.2011; Split Date-Split Factor-Latest Astellas Pharma Inc News. Astellas Pharma reported 21.29 in PE Price to Earnings for its fourth fiscal quarter of 2020. Therapeutic Goods Administration AusPAR Betmiga mirabegron Astellas Pharma Australia Pty Ltd PM-2012-01928-3-3 Date of Finalisation 9 January 2014 Page 2 of 74 About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible …
Farbring Pyramide Holz, Astrazeneca Stock Asx, Mikasa Beach Volleyball Official Ball, Rosamunde Pilcher: Die Braut Meines Bruders Ganzer Film Deutsch, Lego Star Wars 75192, Wegerer E Learning Deutsch, Gehalt Geschäftsführer Startup, Allopurinol 300 Preis, Fisher Price Kinder Kassettenrecorder, Amore Amore Amore Italian Song,